Welcome to our dedicated page for OneMedNet SEC filings (Ticker: ONMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OneMedNet Corp filings document the public-company reporting record for a healthcare data business with common stock and redeemable warrants. Recent 8-K reports cover Nasdaq continued-listing matters, including minimum bid price and market-value compliance notices, along with other material events affecting the company’s public listing status.
Proxy materials describe annual meeting procedures, stockholder voting matters, board composition, and governance disclosures. The filing record also identifies the company’s capital securities, including common stock and redeemable warrants exercisable for common shares, and records director-related governance updates through current reports.
OneMedNet Corp’s chief medical officer and director has filed a Form 3 reporting significant ownership of the company’s common stock. The insider directly holds 2,455,124 shares of common stock and has an additional 1,311,970 shares reported as indirectly owned through a trust for children, where an independent trustee holds investment control and beneficial ownership is disclaimed.
The filing also shows a senior secured convertible note issued under a June 28, 2023 securities purchase agreement, which is convertible into common stock at the lower of $10.00 per share or 92.5% of the lowest volume-weighted average trading price for the ten trading days before conversion, subject to a floor price, with maturity on November 7, 2024. In addition, the insider holds warrants for 31,916 shares of common stock at an exercise price of $10.00 per share, which are immediately exercisable and expire on November 7, 2028.
OneMedNet Corp director reports initial share ownership. A reporting person serving as a director of OneMedNet Corp disclosed beneficial ownership of 237,122 shares of common stock as of an event dated 08/14/2024. The filing is made by a single reporting person and does not list any derivative securities, focusing solely on currently beneficially owned common shares held directly.
OneMedNet Corp director reports no beneficial ownership on Form 3
OneMedNet Corp director filed an initial ownership report stating that no securities of the company are beneficially owned. The filing is made by a single reporting person in the capacity of director, and both the non-derivative and derivative security tables are effectively empty. A remark clarifies that no securities are beneficially owned, and a power of attorney authorizes the attorney-in-fact to sign the form on the reporting person’s behalf.
OneMedNet Corp reported an initial insider ownership filing on Form 3 for a director, with an event date of 02/25/2025. The filing indicates that no securities of OneMedNet Corp are beneficially owned by this reporting person. The form is filed by a single reporting person and is signed by an attorney-in-fact under a power of attorney.
OneMedNet Corp director reports no beneficial ownership on Form 3
A newly reported director of OneMedNet Corp (ONMD) has filed an initial statement of beneficial ownership on Form 3 for an event dated 10/01/2024. The filing identifies the reporting person’s relationship to the company as a Director and confirms that the form is filed by one reporting person only.
In the remarks section, the filing states that no securities are beneficially owned. A Power of Attorney (Exhibit 24) is noted, and the form is signed by an attorney-in-fact on 11/26/2025, documenting that, as of the reported event date, the director does not hold OneMedNet securities in either direct or indirect form.
OneMedNet Corporation filed Prospectus Supplement No. 2 to its Form S-1, registering a primary offering of up to 11,500,000 shares of common stock and a secondary offering of up to 28,152,560 shares for resale. The supplement updates the prospectus dated July 24, 2025 and attaches the company’s Q3 2025 Form 10-Q for the quarter ended September 30, 2025.
The company is an emerging growth company and notes that investing in its securities involves a high degree of risk, directing readers to the Risk Factors section of the prospectus. As context, shares outstanding were 51,005,205 as of November 7, 2025. The supplement must be read together with the base prospectus, and neither the SEC nor any state commission has approved or disapproved the securities.
OneMedNet Corporation reported Q3 2025 results with total revenue of $177K (vs. $142K a year ago), driven by web imaging revenue of $177K as subscription revenue was $0. Gross margin was -$222K, and operating loss was $2.24M. Net loss for the quarter was $741K (vs. $2.06M loss a year ago).
For the nine months, revenue was $468K (vs. $617K in 2024). Despite a $6.59M operating loss, the company recorded $339K net income, primarily from non-operating items, including gains on troubled debt restructurings. Cash was $149K with $600K in Bitcoin (5 units) as of September 30, 2025; total assets were $1.51M against current liabilities of $5.01M, and stockholders’ deficit was -$3.94M. Management states these conditions raise substantial doubt about the ability to continue as a going concern.
The company raised capital through June and August 2025 equity sales and related-party subscriptions, converted debt to equity (PIPE Notes and loan extensions), and repaid the Yorkville note after several conversions. Shares outstanding were 51,005,205 as of November 7, 2025.
OneMedNet Corporation will hold its 2025 Annual Meeting on December 17, 2025 at 11:00 a.m. CT via live audio webcast at https://www.cstproxy.com/onemednet/2025. Stockholders will vote to elect two Class II directors for three-year terms and to ratify WithumSmith+Brown, PC as independent auditor for 2025.
Holders of record on October 23, 2025 may vote; there were 51,157,069 shares of common stock outstanding as of that date. The Board recommends voting FOR both director nominees and FOR auditor ratification. Director Jair Clarke will not stand for re-election; the Board size will be reduced to eight after the meeting.
The Audit Committee reports Withum fees of $840,000 for 2024 (including $790,000 audit and $50,000 tax). BF Borgers was dismissed in May 2024 following an SEC order; its 2023 report included a going concern explanatory paragraph and noted material weaknesses, with no disagreements reported.
Executive updates include RSU awards to leadership and related-party financings and conversions in 2025 involving Dr. Thomas Kosasa and Dr. Jeffrey Yu. As of October 23, 2025, beneficial ownership includes Dr. Kosasa at 30.8% and Dr. Yu at 13.8%.
OneMedNet Corporation announced that director Jair Clarke will not stand for re-election at the Company’s 2025 Annual Meeting of Stockholders. The Company stated his decision was not due to any disagreement with the Company or management. Mr. Clarke will remain on the Board until the Annual Meeting and will continue to serve in an advisory capacity thereafter.
OneMedNet Corporation reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq staff notified the company that, for 10 consecutive business days from September 24, 2025 through October 7, 2025, the closing bid price of its common stock was at least $1.00 per share, satisfying Nasdaq Listing Rule 5550(a)(2). With this notice, the prior bid price deficiency has been resolved and the listing compliance matter is now closed.